Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity

Rheumatoid Arthritis

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Arthritis Rheumatol.

Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR

doi: 10.1002/art.39944.

Psoriatic Arthritis

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Ann Rheum Dis.

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML

doi: 10.1136/annrheumdis-2018-213463.

Rheumatoid Arthritis

Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis

Arthritis Care Res (Hoboken)

Fleischmann R, Liu J, Zhu J, Segurado OG, Furst DE

doi: 10.1002/acr.24583

Rheumatoid Arthritis

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

J Int Med Res.

Conigliaro P, Chimenti MS, Triggianese P, Ballanti E, Sunzini F, Duca I, Perricone R

doi: 10.1177/

Rheumatoid Arthritis

Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5

Arthritis Care Res (Hoboken).

Hoque A, Gallagher K, McEntegart A, Porter D, Steultjens M, Woodburn J, Hendry GJ

doi: 10.1002/acr.24259.

Rheumatoid Arthritis

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Arthritis Res Ther.

Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C

doi: 10.1186/s13075-018-1575-2.

Rheumatoid Arthritis

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes

J Rheumatol.

Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY

doi: 10.3899/jrheum.171375.

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

doi: 10.1016/S0140-

Rheumatoid Arthritis

Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study

Clin Rheumatol.

Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J

doi: 10.1007/s10067-017-3779-2.

Related content

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial